Is Axsome Therapeutics Inc (AXSM) a risky stock?
As of July 21, 2026, Clavix grades Axsome Therapeutics Inc (AXSM) C+ for risk, a composite score of 64 out of 100 on an A+ to F scale, which puts AXSM in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind AXSM's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how AXSM scores on each, as of July 21, 2026.
What's moving AXSM's risk right now
Company-specific signals Clavix flags behind AXSM's current grade, drawn from recent news and filings as of July 21, 2026.
A new institutional investor has taken an initial position in AXSM, which could provide modest support for the stock and signals growing institutional interest in the company.
Jazz faces renewed competitive pressure in the narcolepsy/sleep space from Axsome's AXS-12 while divesting Sunosi, signaling a strategic portfolio reshape that could affect its sl…
The FOCUS-2 dosing milestone signals progress in AXSM's pipeline expansion into pediatric ADHD, but with shares up 37% in 90 days, much of the ADHD upside may already be reflected…
What a C+ grade means
On the Clavix A+ to F scale, AXSM's composite of 64 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell AXSM or any security. Grades are risk indicators, not predictions of return. Data may be delayed.